ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients with Severe Sepsis

Phase 3

Completed

Conditions: Septic shock
Severe sepsis
10002252

Registration Number: NL-OMON31790

Lead Sponsor: Eisai

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 100

Inclusion Criteria

1. Age *18 years; no upper age limit;2. Confirmed early-onset severe sepsis defined as:
a. Objective evidence of infection likely to be caused by a bacterial or fungal pathogen. Examples of objective evidence may include clinical findings (eg, cellulitis or abscesses), cultures, Gram stains, X-rays, and surgical pathology specimens. A positive culture is not a requirement for entry into the trial.
b. Occurrence of at least three of the four SIRS criteria below
These criteria should have occurred between 12 hours before and 4 hours after the onset of the qualifying organ dysfunction.
* Core (central, urinary, esophageal, or rectal) body temperature *36°C or core (preferred), oral, or tympanic body temperature *38°C
Non-core temperatures are not to be adjusted. (revised per Amendment 01)
* Heart rate *90 beats/minute (patients who cannot be assessed for sepsis-induced tachycardia due to another medical condition known to increase heart rate, or those receiving treatment that prevents tachycardia, must have 2 of the remaining 3 SIRS criteria)
* Respiratory rate >20 breaths per minute or a PaCO(2) <32 mm Hg, or mechanical ventilation
* WBC count *12,000 cells/*L, *4000 cells/*L, or >10% band forms;3. At least one of the following organ dysfunctions:
a. Acute Lung Injury (ALI) / Acute Respiratory Distress Syndrome (ARDS):
* Acute onset of all four criteria below must occur together within a 24-hour interval, and the time of organ dysfunction is defined as the time that the final (fourth) criterion occurred:
- PaO(2)/FiO(2) *300 (<200 in patients with pneumonia). If altitude >1000 m, then PaO(2)/FiO(2) *300 x (PB/760).
- Bilateral infiltrates consistent with pulmonary edema on frontal chest radiograph. The infiltrates may be patchy, diffuse, homogeneous, or asymmetric.
- Requirement for positive pressure ventilation via endotracheal tube or tracheostomy tube.
- No clinical evidence of left atrial hypertension.
* No history of severe chronic respiratory disease:
- FEV(1) less than 20 mL/kg PBW (eg, 1.4 L for 70 kg), or
- FEV(1)/VC less than 50% predicted, or
- Chronic hypercapnia (PaCO(2) greater than 45 mm Hg) and/or chronic hypoxemia (PaO(2) <55 mm Hg) on FiO(2) <= 0.21, or
- Radiographic evidence of chronic over-inflation or chronic interstitial infiltration, or
- Hospitalization within the past 6 months for respiratory failure (PaCO(2) >50 mm Hg or PaO(2) <55 mm Hg or O(2)-Sat <88% on FiO(2) <= .21).
- Chronic restrictive, obstructive, neuromuscular, chest wall or pulmonary vascular disease resulting in severe exercise restriction (eg. unable to climb stairs or perform household duties), secondary polycythemia, severe pulmonary hypertension (mean >40 mm Hg), or ventilator dependency.
b. Thrombocytopenia:
* Acute onset of platelet count <100,000 or a reduction of 50% or more from prior known levels, without past history of thrombocytopenia, and without attributable cause other than infection.
c.
* Lactic acidosis: (revised per Amendment 01)
* Unexplained metabolic acidosis (pH <7.30 or a base deficit >5.0 mmol/L) in association with a plasma lactate level >2.2 mmol/L (19.8 mg/dL)
* Subjects receiving parenteral fluids containing lactate are not eligible for inclusion under this criterion.
d. Shock:
* Acute onset of systolic blood pressure <90 mm Hg or mean arterial pressure <65 mm Hg. Blood pressure is poorly resp

Exclusion Criteria

1. Pregnancy or breast feeding;2. Extensive (>20% body surface area) third-degree burns within prior 7 days;3. Patients whose death from sepsis or an underlying condition is considered imminent;4. Patients with an expected survival of less than 2 months due to a pre-existing and uncorrectable medical condition, or those in a chronic vegetative state;5. Patients currently receiving immunosuppressive therapy
Consult Appendix 9 for a list of representative excluded therapies. Any subsequent modification to this list will be in the form of memos to the study sites. For agents not listed, patients should be off such therapies for a time sufficient to restore immune function. (revised per Amendment 02);6. Patients with granulocyte counts <1000/mm(3) unless the decreased count is believed to be due to sepsis;7. Patients who required cardiopulmonary resuscitation in the 4 weeks prior to evaluation for enrollment;8. HIV-positive patients with a last known CD4 count *50/mm(3), or end-stage processes (eg, systemic M. avium infection, progressive multifocal leukoencephalopathy);9. Patients with significant hepatic impairment (Child-Pugh class C), portal hypertension, or esophageal varices;10. Patients with severe congestive heart failure (eg, NYHA Class IV, ejection fraction <35%);11. Weight >150 kg at admission;12. Any one of the following (revised per Amendment 01):
* Ongoing or planned high-flux continuous hemofiltration or hemodiafiltration for the indication of sepsis in the absence of renal impairment
NOTE: Continuous hemofiltration or hemodiafiltration using ultracentrifugation volumes *35 mL/kg/hr for renal replacement therapy, and hemodialysis, are permissible.
* Ongoing or planned use of endotoxin removal devices, such as polymyxin B columns or cartridges
* Ongoing or planned plasma exchange performed for the indication of sepsis;13. IL-2 or interferon therapy within 30 days prior to enrollment ;14. Patients must not have taken any investigational medications or been treated with an investigational device (ie, not approved by the relevant regulatory agency for any indication) within the 30-day period prior to
enrollment into the study.;15. Cancer patients with active disease# or who have not completed their chemotherapy regimen (added per Amendment 01)
* Patients without evidence of active disease may be eligible, provided they have received no cancer chemotherapy or other cancer treatment for a minimum of 3 months (unless a longer exclusionary period is specified for an agent used in treatment) (see Appendix 9).
* Prophylactic use of tamoxifen for prevention of breast cancer is permitted.
* Adjuvant hormonal therapy is permitted.
#Subjects with basal cell carcinoma, cervical carcinoma in situ, or low-grade prostate cancer are eligible.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary objective of this study is to demonstrate that eritoran tetrasodium<br /><br>treatment of patients with severe sepsis results in a reduction in 28-day<br /><br>all-cause mortality.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>The secondary objectives are to confirm eritoran*s safety profile, and to<br /><br>demonstrate the long-term benefit of eritoran treatment (reduction in 12-month<br /><br>mortality), and to determine the population PK profile of eritoran.<br /><br>Exploratory objectives are to determine the effects of eritoran treatment on<br /><br>duration of ICU and overall hospital stay; on the duration of dialysis,<br /><br>mechanical ventilation, or use of vasopressors within 28 days; on inflammatory<br /><br>marker (cytokine) responses, SOFA scores, 3- and 6-month mortality, subsequent<br /><br>infectious<br /><br>episodes, and pharmacoeconomic and quality-of-life (QoL) measures.<br /><br>Appropriateness of initial antibiotic regimen will also be explored. In<br /><br>addition, efficacy and safety measures may be examined using an exploratory<br /><br>population PK/PD analysis.</p><br>

Related Trials